** U.S-listed shares of drug developer NewAmsterdam Pharma NAMS.O fall as much as 5.8%; last down 4.7% at $24.95
** NAMS late Tuesday announced commencement of a $300 mln public offering of shares and pre-funded warrants
** Offering commenced after NAMS terminated up to $150 mln "at-the-market" stock sale agreement with TD Cowen
** Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are the joint book-running managers for the offering
** Stock also rose 41.4% on Tuesday after NAMS reported data from a late-stage study that showed its experimental drug significantly reduced levels of low-density lipoprotein cholesterol
** NAMS has 92.4 mln outstanding shares and a $2.42 bln market capitalization as of last close - LSEG data
** As of last close, NAMS shares had more than doubled YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。